Expression of long non-coding RNA MAGI2‑AS3 in human gliomas and its prognostic significance.

OBJECTIVE:It has been confirmed that the dysregulation of long noncoding RNAs (lncRNAs) is associated with various diseases, especially cancer. LncRNA MAGI2 antisense RNA 3 (MAGI2-AS3) has been reported to be involved in the progression of bladder cancer and breast cancer. In this study, we aimed to explore its expression and clinical significance in glioma. PATIENTS AND METHODS:Quantitative Real (qRT-PCR) assays were performed to detect the expression levels of MAGI2-AS3 in fresh glioma and matched adjacent normal brain tissue specimens, which were collected from 178 patients. Then the association between MAGI2-AS3 expression and clinical-pathological parameters were further evaluated using the Chi-square test. The overall survival (OS) was analyzed by the log-rank test, and the survival curves were plotted according to Kaplan-Meier. Univariate and multivariate analyses were performed to analyze the prognostic significance of MAGI2-AS3 expression. RESULTS:We found that the relative expression level of MAGI2-AS3 in glioma tissues was significantly lower than those in adjacent normal brain tissues (p<0.01). Lower MAGI2-AS3 expression was observed to be positively correlated with the World Health Organization (WHO) grade (p=0.031) and KPS score (p=0.003) in glioma patients. The Kaplan-Meier analysis indicated that patients with low MAGI2-AS3 expression levels tended to have worse overall survival than those with high levels of MAGI2-AS3 expression (p=0.0042). In the multivariate analysis, we further observed that MAGI2-AS3 expression in glioma tissues was an independent prognostic factor for overall survival (HR=3.098, 95% CI: 1.289-4.118, p=0.014). CONCLUSIONS:MAGI2-AS3 expression represents a significant favorable prognostic factor for patients with glioma.

KEYWORDS: {{ getKeywords(articleDetailText.words) }}